GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBPP.PFD) » Definitions » Net Interest Income

RGBPP.PFD (Regen BioPharma) Net Interest Income : $-0.25 Mil (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Regen BioPharma Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Regen BioPharma's net interest income for the three months ended in Sep. 2024 was $-0.18 Mil. Its net interest income for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.25 Mil.

Regen BioPharma Net Interest Income Historical Data

The historical data trend for Regen BioPharma's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Net Interest Income Chart

Regen BioPharma Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.94 -0.37 -0.26 -0.31 -0.25

Regen BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 -0.02 -0.02 -0.02 -0.18

Regen BioPharma Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Net Interest Income Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBPP.PFD) » Definitions » Net Interest Income
Comparable Companies
PXMD ISCO XSNX LADX AXIM EMMA ARTH EVFM MRZM NTBLQ VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
RGBP:USA
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Website
https://www.regenbiopharmainc.com
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.